Bear Creek Capital presents Actinium Pharmaceuticals, Inc. (ATNM)

YOU ARE CORDIALLY INVITED

HOSTS

Dinner & Corporate Presentation

Who: Actinium Pharmaceuticals, Inc.

(NASDAQ: ATNM)

When: Thursday, May 14, 2015

Where: Antonio's

611 S. Orlando Avenue

Maitland, FL 32751

Time: Promptly at 5:30 PM

We hope to see you there!

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies. Its products include Actimab-A, an antibody-drug construct, which includes monoclonal antibody Lintuzumab and alpha emitting radioisotope actinium 225; and is in multicenter Phase I/II clinical trials for acute myeloid leukemia (AML). The company also offers Iomab-B, an antibody-drug construct that comprises the BC8 monoclonal antibody and beta emitting radioisotope iodine 131, and is used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its Iomab-B is in preparation for a Phase III multicenter clinical trial for bone marrow conditioning for HSCT in relapsed and refractory AML patients. The company was founded in 2000 and is based in New York, New York.

To learn more about Actinium Pharmaceuticals, visit our website at http://www.actiniumpharma.com.

In the News

Actinium to Partner With Aplastic Anemia & MDS International Foundation Patient and Family Forums

Actinium Doses the First Patient in the Fourth, Final Cohort of Its Actimab-A Trial

Actinium Pharmaceuticals Opens Enrollment for the Fourth and Final Cohort in the Company's Ongoing Phase I/II Trial in Acute Myeloid Leukemia

Presentation Format:

5:30 p.m. to 6:00 p.m. – Cocktails

6:00 p.m. to 7:00 p.m. – Dinner and Presentation

Contact:

Raymond Oliver

CEO, Bear Creek Capital

321-439-2120

roliver@bearcreekcap.com